Denali therapeutics announces fast track designation granted by the u.s. fda to etv:ids (dnl310) for the treatment of patients with hunter syndrome (mps ii)

South san francisco, calif., march 11, 2021 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced that the u.s. food and drug administration (fda) has granted fast track designation to etv:ids (dnl310) for the treatment of patients with hunter syndrome (mps ii). dnl310, denali's lead investigational brain-penetrant enzyme replacement therapy, is under evaluation in a phase 1/2 study in patients with hunter syndrome as a potential treatment for both central nervous system (cns) and peripheral manifestations of the disease.
DNLI Ratings Summary
DNLI Quant Ranking